Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia
# Purpose of Review This is a comprehensive review of the literature regarding the use of Lumateperone tosylate for schizophrenia. This review presents the background, evidence, and indications for the use of lumateperone tosylate in the treatment of schizophrenia. # Recent Findings Schizophreni...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Medical Publishing
2021-06-01
|
| Series: | Health Psychology Research |
| Online Access: | https://doi.org/10.52965/001c.24932 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825139374505852928 |
|---|---|
| author | Kunal Maini Janice W. Hollier Haley Gould Victoria Bollich John LaForge Elyse M. Cornett Amber N. Edinoff Adam M. Kaye Alan D. Kaye |
| author_facet | Kunal Maini Janice W. Hollier Haley Gould Victoria Bollich John LaForge Elyse M. Cornett Amber N. Edinoff Adam M. Kaye Alan D. Kaye |
| author_sort | Kunal Maini |
| collection | DOAJ |
| description | # Purpose of Review
This is a comprehensive review of the literature regarding the use of Lumateperone tosylate for schizophrenia. This review presents the background, evidence, and indications for the use of lumateperone tosylate in the treatment of schizophrenia.
# Recent Findings
Schizophrenia is a chronic mental health disorder that affects approximately 3.3 million people in the United States. Its symptoms, which must be present more than six months, are comprised of disorganized behavior and speech, a diminished capacity to comprehend reality, hearing voices unheard by others, seeing things unseen by others, delusions, decreased social commitment, and decreased motivation. The majority of these symptoms can be managed with antipsychotic medication.
Lumateperone is a selective and concurrent modulator of serotonin, dopamine, and glutamate, which all mediate or modulate serious mental illness.
# Summary
Schizophrenia is a complex, severe mental illness that affects how the brain processes information. There are many medications used to treat schizophrenia. One antipsychotic agent, lumateperone tosylate, is a newer agent that the FDA recently approved. The most common adverse effects are shown to be mild such as somnolence, constipation, sedation, and fatigue, with the 42 mg recommended dose. Lumateperone tosylate is an FDA-approved drug that can be given only at the 42mg dose once daily with no titration requirements. |
| format | Article |
| id | doaj-art-17caaf12d8ac4d389e4579ec9369ac59 |
| institution | Kabale University |
| issn | 2420-8124 |
| language | English |
| publishDate | 2021-06-01 |
| publisher | Open Medical Publishing |
| record_format | Article |
| series | Health Psychology Research |
| spelling | doaj-art-17caaf12d8ac4d389e4579ec9369ac592025-02-11T20:30:32ZengOpen Medical PublishingHealth Psychology Research2420-81242021-06-0191Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of SchizophreniaKunal MainiJanice W. HollierHaley GouldVictoria BollichJohn LaForgeElyse M. CornettAmber N. EdinoffAdam M. KayeAlan D. Kaye# Purpose of Review This is a comprehensive review of the literature regarding the use of Lumateperone tosylate for schizophrenia. This review presents the background, evidence, and indications for the use of lumateperone tosylate in the treatment of schizophrenia. # Recent Findings Schizophrenia is a chronic mental health disorder that affects approximately 3.3 million people in the United States. Its symptoms, which must be present more than six months, are comprised of disorganized behavior and speech, a diminished capacity to comprehend reality, hearing voices unheard by others, seeing things unseen by others, delusions, decreased social commitment, and decreased motivation. The majority of these symptoms can be managed with antipsychotic medication. Lumateperone is a selective and concurrent modulator of serotonin, dopamine, and glutamate, which all mediate or modulate serious mental illness. # Summary Schizophrenia is a complex, severe mental illness that affects how the brain processes information. There are many medications used to treat schizophrenia. One antipsychotic agent, lumateperone tosylate, is a newer agent that the FDA recently approved. The most common adverse effects are shown to be mild such as somnolence, constipation, sedation, and fatigue, with the 42 mg recommended dose. Lumateperone tosylate is an FDA-approved drug that can be given only at the 42mg dose once daily with no titration requirements.https://doi.org/10.52965/001c.24932 |
| spellingShingle | Kunal Maini Janice W. Hollier Haley Gould Victoria Bollich John LaForge Elyse M. Cornett Amber N. Edinoff Adam M. Kaye Alan D. Kaye Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia Health Psychology Research |
| title | Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia |
| title_full | Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia |
| title_fullStr | Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia |
| title_full_unstemmed | Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia |
| title_short | Lumateperone tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia |
| title_sort | lumateperone tosylate a selective and concurrent modulator of serotonin dopamine and glutamate in the treatment of schizophrenia |
| url | https://doi.org/10.52965/001c.24932 |
| work_keys_str_mv | AT kunalmaini lumateperonetosylateaselectiveandconcurrentmodulatorofserotonindopamineandglutamateinthetreatmentofschizophrenia AT janicewhollier lumateperonetosylateaselectiveandconcurrentmodulatorofserotonindopamineandglutamateinthetreatmentofschizophrenia AT haleygould lumateperonetosylateaselectiveandconcurrentmodulatorofserotonindopamineandglutamateinthetreatmentofschizophrenia AT victoriabollich lumateperonetosylateaselectiveandconcurrentmodulatorofserotonindopamineandglutamateinthetreatmentofschizophrenia AT johnlaforge lumateperonetosylateaselectiveandconcurrentmodulatorofserotonindopamineandglutamateinthetreatmentofschizophrenia AT elysemcornett lumateperonetosylateaselectiveandconcurrentmodulatorofserotonindopamineandglutamateinthetreatmentofschizophrenia AT ambernedinoff lumateperonetosylateaselectiveandconcurrentmodulatorofserotonindopamineandglutamateinthetreatmentofschizophrenia AT adammkaye lumateperonetosylateaselectiveandconcurrentmodulatorofserotonindopamineandglutamateinthetreatmentofschizophrenia AT alandkaye lumateperonetosylateaselectiveandconcurrentmodulatorofserotonindopamineandglutamateinthetreatmentofschizophrenia |